Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

AstraZeneca Looks To Prove Itself In The Type 2 Diabetes Market

11h seekingalpha
AstraZeneca announced positive results for type 2 diabetes patients with renal impairment who were treated with its SGLT2 inhibitor FARXIGA. (43-0)

4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18

19h zacks
GlaxoSmithKline plc (GSK - Free Report) focuses on three core businesses – Pharmaceuticals, Vaccines and Consumer Healthcare. Glaxo enjoys strong fundamentals in the form of its diversified base and presence in different geographical areas. (25-0)

Geron's Negative Imetelstat Data Has Been Misinterpreted By Investors

19h seekingalpha
We believe IMbark may have a healthier patient population which explains the longer than expected overall survival. (46-1)

Arena's Positive Phase 2 Ulcerative Colitis Data Is An Added Bonus

2018-03-21 seekingalpha
Arena has already posted positive phase 2 data using its drug Ralinepag to treat patients with Pulmonary arterial hypertension. (8-0)

Vistagen - Nanocap CNS Drug Chasing Ketamine Fame

2018-03-21 seekingalpha
The drug is following in the footsteps of Ketamine, which has shown great promise for depression. (5-0)

U.S. Quality Dividend Growth: An Alternative To The S&P 500

2018-03-21 seekingalpha
We are coming up on five years since we launched the WisdomTree U.S. Quality Dividend Growth Fund (NASDAQ:DGRW) our $2.13 billion ETF1 that tracks the WisdomTree U.S. Quality Dividend Growth Index. Its benchmark is the NASDAQ US Dividend Achievers Select Index, but figure 1 also includes the S&P High Yield Dividend Aristocrats and the S&P 500 Indexes. (39-0)

JNJ / Johnson & Johnson 8-K (Current Report)

Document UNITED STATES (5-0)

Johnson & Johnson: Dividend Hike Ahead

2018-03-20 seekingalpha
JNJ has grown its dividend for 55 consecutive years and its adjusted operating earnings for 34 consecutive years. (106-0)

10 Dividend Growth Stocks For March 2018

2018-03-20 seekingalpha
I rank a selection of David Fish's CCC dividend growth stocks. The top 10 ranked stocks are great candidates for further analysis. (130-0)

Biotechs Approaching New Waters

2018-03-20 seekingalpha
The biotech sector also continues to benefit from potential M&A, faster drug approvals, strong risk appetite, and improving public sentiment. (727-5)

7 Dividend Funds for Your 401k

2018-03-20 investorplace
If you’re looking for the best dividend funds for your 401(k) plan, whether you’re an employee investing for retirement or an employer looking for good funds to include your plan, there are a handful of key qualities to look for. (205-0)

Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus

2018-03-20 zacks
Emerging market investment has taken a backseat of late, thanks to the nonstop blows to the economy. The lingering geopolitical tension in Gulf, debt and policy related hazards in Latin America or the missile tests in North Korea have led stock investors to reconsider their outlay in these markets, earlier proclaimed to offer better growth opportunities than the United States. Going by the MSCI Emerging Markets Index, the last five-year annualized growth rate was just 5. (48-0)

Your Daily Pharma Scoop: Heron's HTX-011, Geron Update, Cidara Tumbles

2018-03-20 seekingalpha
Heron Therapeutics (NASDAQ:HRTX) shares have surged today as the company announced that its HTX-011 succeeded in a late-stage study. (121-0)

Orthopedic Device Market Gains Momentum: 3 Stocks in Focus

2018-03-19 zacks
“At some point in every person's life, you will need an assisted medical device … as you age and you have a hip replacement or a knee replacement or a pacemaker.” (41-0)

J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit

2018-03-19 zacks
Johnson & Johnson (JNJ - Free Report) announced that it has received a binding offer of approximately $2.1 billion from a private equity firm, Platinum Equity, for its LifeScan diabetes device unit. The LifeScan unit makes blood glucose monitoring products and generated revenues of $1.5 billion last year. (95-0)

CUSIP: 478160104